Analysts at Brean Capital began coverage on shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) in a note issued to investors on Tuesday. The brokerage set a “buy” rating and a $16.00 price target on the biopharmaceutical company’s stock. Brean Capital’s price objective would indicate a potential upside of 264.46% from the stock’s previous close.
Other analysts also recently issued reports about the company. Jefferies Group increased their target price on Celldex Therapeutics to $5.00 and gave the company a “hold” rating in a research note on Friday, August 5th. Wedbush reiterated a “neutral” rating and set a $3.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating and set a $12.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, June 7th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $9.75.
Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 4.39 on Tuesday. The company’s 50 day moving average price is $3.75 and its 200-day moving average price is $4.16. The company’s market capitalization is $441.39 million. Celldex Therapeutics has a 1-year low of $2.96 and a 1-year high of $18.62.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The company earned $1.39 million during the quarter, compared to analyst estimates of $0.96 million. During the same quarter last year, the company earned ($0.33) EPS. The firm’s revenue for the quarter was down 36.4% on a year-over-year basis. On average, equities analysts forecast that Celldex Therapeutics will post ($1.34) earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA increased its position in Celldex Therapeutics by 31.1% in the third quarter. BNP Paribas Arbitrage SA now owns 147,084 shares of the biopharmaceutical company’s stock valued at $594,000 after buying an additional 34,851 shares during the period. Schwab Charles Investment Management Inc. increased its position in Celldex Therapeutics by 6.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 339,154 shares of the biopharmaceutical company’s stock valued at $1,489,000 after buying an additional 19,418 shares during the period. Numeric Investors LLC increased its position in Celldex Therapeutics by 61.7% in the second quarter. Numeric Investors LLC now owns 639,600 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 244,000 shares during the period. RTW Investments LLC increased its position in Celldex Therapeutics by 27.8% in the second quarter. RTW Investments LLC now owns 1,264,227 shares of the biopharmaceutical company’s stock valued at $5,550,000 after buying an additional 274,851 shares during the period. Finally, Veritable L.P. bought a new position in Celldex Therapeutics during the second quarter valued at $132,000. Institutional investors own 78.41% of the company’s stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.